Rachel Sosland, MD
Cardiovascular Disease · Overland Park, KSNPI 1023173929
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $25,500 of the $32,619 with a category attached, or 78.2%. ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) accounts for 83.0% of it on its own, with 33 other manufacturers making up the rest. Reporting peaked in 2023 at $8,709 and has fallen 92.4% since, to $666 in 2025. Among cardiovascular disease clinicians in KS with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 348 payments — averaging $93.73 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)$27K
- Johnson & Johnson$601
- Amgen$545
- Sanofi-aventis U.S. LLC$473
- Boston Scientific$464
- Medtronic$421
- plus $3K from 28 others
What the payments were for
- Consulting fees$200%
- Speaking & faculty fees$25,50078%
- Travel & lodging$2141%
- Food & beverage$6,52020%
- Education$3651%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 70 | $27,084 |
| Johnson & Johnson | 41 | $601 |
| Amgen | 31 | $545 |
| Sanofi-aventis U.S. LLC | 25 | $473 |
| Boston Scientific | 21 | $464 |
| Medtronic | 6 | $421 |
| Boehringer Ingelheim | 25 | $382 |
| Pfizer | 19 | $376 |
| Abbott | 5 | $313 |
| Novartis | 22 | $309 |
| Irhythm Technologies, Inc. | 11 | $246 |
| Novo Nordisk | 11 | $222 |
| Astellas Pharma US Inc | 3 | $222 |
| AstraZeneca | 12 | $185 |
| Philips North America LLC | 9 | $140 |
| E.r. Squibb & Sons, L.L.C. | 9 | $139 |
| Regeneron Healthcare Solutions, Inc. | 3 | $51 |
| Vital Connect, Inc | 3 | $50 |
| Amarin Pharma, Inc. | 3 | $47 |
| Kestra Medical Technology Services, Inc. | 2 | $44 |
| Lemaitre Vascular, Inc. | 1 | $43 |
| Merck | 2 | $31 |
| Alnylam Pharmaceuticals Inc. | 2 | $30 |
| Edwards Lifesciences | 1 | $25 |
| Esperion Therapeutics, Inc. | 2 | $24 |
| Tactile Systems Technology Inc | 1 | $24 |
| Z-medica, LLC | 1 | $20 |
| Bayer | 1 | $18 |
| Kiniksa Pharmaceuticals International, PLC | 1 | $17 |
| Infobionic, Inc | 1 | $17 |
| Actelion Pharmaceuticals US, Inc. | 1 | $15 |
| Heartflow, Inc. | 1 | $14 |
| Kowa Pharmaceuticals America, Inc. | 1 | $13 |
| Gilead | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$32,619 in reported general payments places this provider in the 95th percentile of 175 cardiovascular disease providers in Kansas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 271 | $353,652 |
| Repatha SureclickEvolocumab | 166 | $188,209 |
| XareltoRivaroxaban | 74 | $105,064 |
| EntrestoSacubitril/Valsartan | 79 | $90,691 |
| JardianceEmpagliflozin | 64 | $88,391 |
| Repatha SyringeEvolocumab | 46 | $56,390 |
| Praluent PenAlirocumab | 34 | $29,755 |
| MultaqDronedarone Hcl | 12 | $19,113 |
| NexletolBempedoic Acid | 14 | $7,020 |
| Ezetimibe | 315 | $6,784 |
| Flecainide Acetate | 101 | $6,196 |
| Atorvastatin Calcium | 506 | $5,145 |
| Metoprolol Succinate | 388 | $4,898 |
| Rosuvastatin Calcium | 479 | $4,816 |
| Losartan Potassium | 364 | $4,009 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $376 | $353,652271 claims |
| Johnson & JohnsonXarelto | $601 | $105,06474 claims |
| NovartisEntresto | $309 | $90,69179 claims |
| Boehringer IngelheimJardiance | $382 | $88,39164 claims |
| Sanofi-aventis U.S. LLCMultaq | $473 | $19,11312 claims |
| Esperion Therapeutics, Inc.Nexletol | $24 | $7,02014 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 175 cardiovascular disease providers in Kansas.
Other cardiovascular disease in Overland Park
- Vasvi SinghOverland Park$405K
- Ahmed ElballatOverland Park$22K
- Paul NagerOverland Park$10K
- Ronnie SmallingOverland Park$9K
- van JonesOverland Park$7K
- Alan SchneiderOverland Park$6K
- Theodore PopeOverland Park$5K
- Stephen BloomOverland Park$5K
- James MarcumOverland Park$4K
- Bassem ChehabWichita$482K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.